Ocuphire Pharma Inc. (OCUP) NASDAQ

$1.96 -0.05 (-2.49%)

Market Cap: $38.92M

As of 06/28/22 04:30 PM EDT. Market closed.

(OCUP)

Ocuphire Pharma Inc. (OCUP) NASDAQ

$1.96 -0.05 (-2.49%)

Market Cap: $38.92M

As of 06/28/22 04:30 PM EDT. Market closed.

Ocuphire is a publicly traded, clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire's pipeline currently includes two small- molecule product candidates targeting front and back of the eye indications. The company's lead product candidate, Nyxol® Eye Drops, is a once-dailypreservative-free ... read more

Ocuphire is a publicly traded, clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire's pipeline currently includes two small- molecule product candidates targeting front and back of the eye indications. The company's lead product candidate, Nyxol® Eye Drops, is a once-dailypreservative-free eye drop formulation of phentolamine mesylate, a non-selectivealpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, and is being developed for several indications, including dim light or night vision disturbances (NVD), reversal pharmacologically-induced mydriasis (RM), and presbyopia. Ocuphire's second product candidate, APX3330, is a twice- a-day oral tablet, designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy (DR) and diabetic macular edema (DME). Nyxol is entering Phase 3 clinical development for NVD and RM, and Phase 2 for presbyopia. APX3330 is entering Phase 2 clinical development for DR/DME. As part of its strategy, Ocuphire will continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late stage development, regulatory preparation and commercialization of drugs in key global markets. read less

COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO
Douglas Swirsky
Full Time Employees
5
URL
Address
15245 Shady Grove Rd Ste 455, Maryland, Rockville, 20850-7203.
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO
Douglas Swirsky
Full Time Employees
5
Address
15245 Shady Grove Rd Ste 455, Maryland, Rockville, 20850-7203.
PRICE CHART
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
KEY STATS
Open
$1.99
Previous Close
$2.01
Days Range
$1.96 - $2.03
52 week range
$1.78 - $7
Volume
25,362
Avg. Volume (30 days)
101,626
Market Cap
$38.92M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
19,364,367
Open
$1.99
Previous Close
$2.01
Days Range
$1.96 - $2.03
52 week range
$1.78 - $7
Volume
25,362
Avg. Volume (30 days)
101,626
Market Cap
$38.92M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
19,364,367

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR OCUPHIRE PHARMA INC
Owner Relationship Date Transaction Cost # Shares Value($) Total Shares Form 4
MANUSO JAMES S J Director May 20, 2022 Buy $1.99 5,000 9,950 21,570 May 24, 2022, 09:43 AM
Sooch Mina President and CEO May 20, 2022 Buy $2.02 12,500 25,300 425,022 May 23, 2022, 04:58 PM
Sooch Mina President and CEO May 19, 2022 Buy $2.07 12,500 25,879 412,522 May 23, 2022, 04:58 PM
Pepose Jay Director Dec 13, 2021 Buy $3.65 8,250 30,113 22,994 Dec 14, 2021, 08:44 PM
MANUSO JAMES S J Director Nov 18, 2021 Buy $3.50 2,000 7,000 16,570 Nov 22, 2021, 04:01 PM
Pepose Jay Director Sep 13, 2021 Buy $4.75 12,631 59,997 14,744 Sep 15, 2021, 08:00 AM
Benton Susan Director Sep 02, 2021 Buy $4.57 20,000 91,400 23,976 Sep 03, 2021, 04:02 PM
Beever Charles Director Jan 31, 2019 Buy $0.64 10,000 6,380 11,000 Feb 04, 2019, 04:53 PM
Price Ben Gil Director Jan 29, 2019 Buy $0.61 15,000 9,141 15,000 Jan 31, 2019, 07:56 AM
Nolan Lisa Chief Business Officer Jan 30, 2019 Buy $0.65 20,000 12,960 21,625 Jan 31, 2019, 07:48 AM
Swirsky Douglas J President and CEO Jan 29, 2019 Buy $0.63 50,000 31,720 50,000 Jan 30, 2019, 07:32 AM
Suzdak Peter David Chief Executive Officer Aug 16, 2017 Option Exercise $1.99 10,000 19,872 16,000 Aug 16, 2017, 04:05 PM
Ahn Chang Ho Director Apr 10, 2017 Option Exercise $0.31 250,000 77,500 6,260,000 Apr 12, 2017, 05:26 PM
Ahn Chang Ho Director Apr 10, 2017 Sale $0.70 250,000 175,375 6,010,000 Apr 12, 2017, 05:26 PM
Suzdak Peter David Chief Executive Officer Mar 18, 2016 Option Exercise $0.32 60,000 19,386 60,000 Mar 21, 2016, 09:20 PM
Jeong Tae Heum Chief Financial Officer Jan 08, 2015 Option Exercise $0.80 78,782 63,026 583,782 Jan 12, 2015, 06:22 PM
Jeong Tae Heum Chief Financial Officer Jan 12, 2015 Option Exercise $0.80 49,800 39,840 554,800 Jan 12, 2015, 06:22 PM
Jeong Tae Heum Chief Financial Officer Jan 09, 2015 Option Exercise $0.80 188,690 150,952 693,690 Jan 12, 2015, 06:22 PM
Jeong Tae Heum Chief Financial Officer Jan 12, 2015 Sale $0.91 49,800 45,492 505,000 Jan 12, 2015, 06:22 PM
Jeong Tae Heum Chief Financial Officer Jan 09, 2015 Sale $0.92 188,690 172,708 505,000 Jan 12, 2015, 06:22 PM
Jeong Tae Heum Chief Financial Officer Jan 08, 2015 Sale $0.90 78,782 70,935 505,000 Jan 12, 2015, 06:22 PM
Ahn Chang Ho Director Jan 08, 2015 Option Exercise $0.80 80,000 64,000 6,090,000 Jan 12, 2015, 06:11 PM
Ahn Chang Ho Director Jan 12, 2015 Option Exercise $0.80 48,444 38,755 6,058,444 Jan 12, 2015, 06:11 PM
Ahn Chang Ho Director Jan 09, 2015 Option Exercise $0.80 186,212 148,970 6,196,212 Jan 12, 2015, 06:11 PM
Ahn Chang Ho Director Jan 12, 2015 Sale $0.91 48,444 44,263 6,010,000 Jan 12, 2015, 06:11 PM
Ahn Chang Ho Director Jan 09, 2015 Sale $0.92 186,212 170,477 6,010,000 Jan 12, 2015, 06:11 PM
Ahn Chang Ho Director Jan 08, 2015 Sale $0.90 80,000 72,032 6,010,000 Jan 12, 2015, 06:11 PM
Ahn Chang Ho Director Jun 12, 2014 Option Exercise $0.80 136,193 108,954 6,950,117 Jun 16, 2014, 07:48 PM
Ahn Chang Ho Director Jun 12, 2014 Sale $0.99 136,193 134,436 6,813,924 Jun 16, 2014, 07:48 PM
McIntosh David M Director Apr 14, 2014 Option Exercise $1.01 99,010 100,000 25,990 Apr 16, 2014, 04:18 PM
McIntosh David M Director Apr 14, 2014 Option Exercise $0.80 125,000 100,000 125,000 Apr 16, 2014, 04:18 PM
Jeong Tae Heum Chief Financial Officer Sep 09, 2013 Option Exercise $0.46 78,861 36,000 576,139 Sep 11, 2013, 06:01 PM
Jeong Tae Heum Chief Financial Officer Sep 09, 2013 Option Exercise $0.24 150,000 36,000 655,000 Sep 11, 2013, 06:01 PM
Jeong Tae Heum Chief Financial Officer Sep 09, 2013 Sale $0.46 71,139 32,475 505,000 Sep 11, 2013, 06:01 PM
Kivel Richard Director Oct 03, 2011 Buy $1.04 2,500 2,600 2,500 Oct 21, 2011, 04:41 PM
Brandt Peter C. Director Sep 08, 2011 Buy $1.10 45,000 49,284 70,000 Sep 12, 2011, 04:38 PM
Brandt Peter C. Director Sep 09, 2011 Buy $1.22 80,000 97,571 150,000 Sep 12, 2011, 04:38 PM
Brandt Peter C. Director Sep 07, 2011 Buy $1.04 5,000 5,200 25,000 Sep 08, 2011, 05:54 PM
Brandt Peter C. Director Sep 06, 2011 Buy $0.95 20,000 18,923 20,000 Sep 08, 2011, 05:54 PM
Ahn Chang Ho Chairman & CEO May 18, 2011 Buy $1.31 1,008,078 1,320,582 11,338,924 May 20, 2011, 04:30 PM
Ahn Chang Ho Chairman & CEO Apr 01, 2011 Buy $1.22 320,846 391,432 10,330,846 Apr 05, 2011, 05:00 PM
Load More Insider Transactions
Buy Sale Option Exercise
Owner Relationship Date Value($)
MANUSO JAMES S J Director 05/20/2022 9,950
Sooch Mina President and CEO 05/20/2022 25,300
Sooch Mina President and CEO 05/19/2022 25,879
Pepose Jay Director 12/13/2021 30,113
MANUSO JAMES S J Director 11/18/2021 7,000
Pepose Jay Director 09/13/2021 59,997
Benton Susan Director 09/02/2021 91,400
Beever Charles Director 01/31/2019 6,380
Price Ben Gil Director 01/29/2019 9,141
Nolan Lisa Chief Business Officer 01/30/2019 12,960
Swirsky Douglas J President and CEO 01/29/2019 31,720
Suzdak Peter David Chief Executive Officer 08/16/2017 19,872
Ahn Chang Ho Director 04/10/2017 77,500
Ahn Chang Ho Director 04/10/2017 175,375
Suzdak Peter David Chief Executive Officer 03/18/2016 19,386
Jeong Tae Heum Chief Financial Officer 01/08/2015 63,026
Jeong Tae Heum Chief Financial Officer 01/12/2015 39,840
Jeong Tae Heum Chief Financial Officer 01/09/2015 150,952
Jeong Tae Heum Chief Financial Officer 01/12/2015 45,492
Jeong Tae Heum Chief Financial Officer 01/09/2015 172,708
Jeong Tae Heum Chief Financial Officer 01/08/2015 70,935
Ahn Chang Ho Director 01/08/2015 64,000
Ahn Chang Ho Director 01/12/2015 38,755
Ahn Chang Ho Director 01/09/2015 148,970
Ahn Chang Ho Director 01/12/2015 44,263
Ahn Chang Ho Director 01/09/2015 170,477
Ahn Chang Ho Director 01/08/2015 72,032
Ahn Chang Ho Director 06/12/2014 108,954
Ahn Chang Ho Director 06/12/2014 134,436
McIntosh David M Director 04/14/2014 100,000
McIntosh David M Director 04/14/2014 100,000
Jeong Tae Heum Chief Financial Officer 09/09/2013 36,000
Jeong Tae Heum Chief Financial Officer 09/09/2013 36,000
Jeong Tae Heum Chief Financial Officer 09/09/2013 32,475
Kivel Richard Director 10/03/2011 2,600
Brandt Peter C. Director 09/08/2011 49,284
Brandt Peter C. Director 09/09/2011 97,571
Brandt Peter C. Director 09/07/2011 5,200
Brandt Peter C. Director 09/06/2011 18,923
Ahn Chang Ho Chairman & CEO 05/18/2011 1,320,582
Ahn Chang Ho Chairman & CEO 04/01/2011 391,432
Load More Insider Transactions
CHANGE IN SHARES OUTSTANDING
STOCK BUYBACKS
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
12/31/2021
09/30/2021
7.31%
1Q
12/31/2021
06/30/2021
21.01%
2Q
12/31/2021
03/31/2021
35.97%
3Q
12/31/2021
12/31/2017
-45.77%
16Q
Load More

Period of Report: 12/31/2021

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
09/30/2021
7.31%
1Q
06/30/2021
21.01%
2Q
03/31/2021
35.97%
3Q
12/31/2017
-45.77%
16Q
Load More